Table 3.
Report on all papers about axitinib and stomatitis.
| Authors | Year | Neoplasia | Number of cases | Stomatitis number | Stomatitis grade 1 |
Stomatitis grade 2 | Stomatitis grade 3 | Stomatitis grade 4 | |
|---|---|---|---|---|---|---|---|---|---|
| (1) | Rugo et al. [58] | 2005 | Phase I study Advanced solid tumors A: AG-013736 Axitinib 5–30 mg in 28-day cycle |
A: 36 | A: 4 (11%) | A: 2 (6%) | A: 2 (6%) | ||
|
| |||||||||
| (2) | Ueda et al. [56] | 2013 | Metastatic renal cell carcinoma A: axitinib B: sorafenib |
A: 359 B: 355 |
A: 54 (15.04%) B: 44 (12.39%) |
A: 49 (13.64%) B: 43 (12.11%) |
A: 5 (1.39%) B: 1 (0.28%) |
||
|
| |||||||||
| (3) | Karam et al. [59] | 2014 | Phase II trial of locally advanced nonmetastatic clear cell renal carcinoma A: axitinib 5 mg for up to 12 weeks |
A: 24 | A: 17 (70.8%) | A: 16 (67%) | A: 1 (4.2%) | ||
|
| |||||||||
| (4) | Oh et al. [60] | 2015 | Phase I study: previously untreated advanced gastric cancer A: axitinib 5 mg twice a day (days 1 to 21) with cisplatin 80 mg/m2 (day 1) and capecitabine 1,000 mg/m2 twice a day (days 1 to 14) in 21-day cycles |
A: 22 | A: 16 (72.7%) | A: 12 (54.5%) | A: 4 (18.2%) | ||
|
| |||||||||
| Total | 441 | 91 (20.63%) | 79 (17.91%) | 12 (2.72%) | |||||